28.11.2023 - NEWTOWN, Pa., Nov. 28, 2023 (GLOBE NEWSWIRE) - Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”, the “Company”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today .
Operator: Ladies and gentlemen, thank you for standing by. Welcome to Onconova Therapeutics Third Quarter 2023 Financial Results and Business Update Conference Call.
Preclinical data indicate that narazaciclib shows monotherapy and combination anti-tumor activity in ibrutinib-sensitive and resistant cells and xenograft models NEWTOWN, Pa., Nov. 02, 2023 .
Reporting responses in patients with RDEB-associated SCC, a devastating disease with a significant unmet needNEWTOWN, Pa., Oct. 12, 2023 (GLOBE NEWSWIRE) (GLOBE NEWSWIRE) Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”, the “Company”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that a late-breaking abstract studying rigosertib in patients with recessive dystrophic epidermolysis bullosa (R
Onconova Therapeutics, Inc. (NASDAQ:ONTX) Q2 2023 Earnings Call Transcript August 10, 2023 Onconova Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.2, expectations were $-0.29. Operator: Ladies and gentlemen, thank you for standing by. Welcome to the Onconova Therapeutics Second Quarter [Technical Difficulty] Dr. Steve Fruchtman: Sarah, excuse me, you are coming in and out […]